Vertex Pharmaceuticals aims to CRISPR Therapeutics’ gene-editing technology to develop type 1 diabetes cell therapies that don’t prompt the immune system to reject them. This approach could compete with a Sana Biotechnology program expected to reach its first test in humans this year.
Jeffrey Davis, Michael Hess and Shannon Wiley, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
During a panel at the AHIP Medicare, Medicaid, Duals and Commercial Markets Forum, three executives were asked what gives them comfort about the return to Medicaid redeterminations, as well as what worries them. One CMS official said she's pleased that states are ramping up communication efforts for Medicaid enrollees, but is concerned about the "insurmountable task" ahead.
In recent years, manufacturers have restricted access to 340B pricing for drugs dispensed through contract pharmacies. The federal government has advised manufacturers that such restrictions are unlawful, and manufactures have challenged government enforcement actions in federal court.
Pharming Group drug Joenja was awarded FDA approval for treating a primary immunodeficiency called activated phosphoinositide 3-kinase delta syndrome, or APDS. It’s the first treatment for the rare disorder.